SPDR® S&P Biotech ETF is a well-diversified, low-cost ETF that can be an excellent tool to capitalize on the potential of the biotech stock sector. XBI's performance should be compared with the ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Happy Monday. So, we’ve got a welcome bump in the XBI, see that European ...

A smart beta exchange traded fund, the SPDR S&P Biotech ETF (XBI) debuted on 01/31/2006, and offers broad exposure to the Health Care ETFs category of the market. Products that are based on market cap ...

The State Street SPDR S&P Biotech ETF (XBI) was launched on January 31, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello, everyone. Damian here with a look at biotech’s latest nadir, the ...

Biotech stocks have staged an impressive rally over the past six months, with the XBI index – key benchmark for small and mid-cap biotech names – posting one of its strongest stretches on record.

The SPDR S&P Biotech ETF (XBI) made its debut on 01/31/2006, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market. The ETF industry has ...